Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: ted who wrote (189)	3/30/1999 9:07:00 AM
From: Vendit™	Read Replies (1) \| Respond to of 557

Targeted Genetics Announces Positive Findings in Phase I/II Clinical Trial Testing Gene Therapy in Chronic Sinusitis in Cystic Fibrosis Patients - Data Support That Delivery of CFTR Gene by Company's Proprietary AAV Vector Reduced Sinus Inflammation - SEATTLE, March 30 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN - news) today announced findings from a Phase I/II clinical trial of tgAAV-CF, the company's proprietary gene therapy product for the treatment of cystic fibrosis (CF). In this blinded, placebo-controlled trial, conducted at Stanford University, 23 cystic fibrosis patients were treated with tgAAV-CF in one maxillary sinus and with placebo in the other. There were no adverse events related to the test agent. Results from the study indicate that inflammation was reduced in sinuses treated with tgAAV-CF and not in sinuses treated with placebo. Full results of the study are being prepared for scientific review and publication. ''We are encouraged by this finding,'' said Darrell J. Salk, M.D., Vice President, Clinical Affairs at Targeted Genetics. ''We have observed a biologic effect associated with treatment with our gene therapy product in a proposed model of CF lung disease. Because the degree of inflammation correlates with the amount of active disease, a reduction in inflammation is a positive sign. Further studies are clearly needed to assess the clinical impact of such an effect in CF lung disease. We are therefore moving forward expeditiously with Phase I testing of an aerosolized version of tgAAV-CF.'' biz.yahoo.com